论文部分内容阅读
基于脂质体或聚合物的纳米粒药物释放系统(DDS)可改善非经肠给药的药理学和治疗性质。早期阻碍微粒型 DDS 临床应用的许多问题已被克服。几种药物的 DDS 制剂已用于临床。此外,根据蛋白质学和基因组学研制出的新药的体内释药系统及其配体靶向疗法应用的优点已引起极大关注。
Liposome- or polymer-based nanoparticulate drug delivery systems (DDSs) may improve the pharmacological and therapeutic properties of parenteral administration. Many of the problems that hinder the clinical use of particulate DDS have been overcome. DDS formulations of several drugs have been used clinically. In addition, the advantages of in vivo drug delivery systems based on proteomics and genomics developed for new drugs and their use of ligand targeted therapies have drawn great attention.